



REVIEW ARTICLE / ПРЕГЛЕДНИ РАД

Atopic dermatitis – novel insights in the immunopathology of the disease

Sanja Jakovljević^{1,2}, Iva Barjaktarović^{3,4}, Dunja Jakovljević⁵, Olivera Levakov^{1,2}, Ljuba Vujanović^{1,2}

¹University of Novi Sad, Faculty of Medicine, Department of Dermatovenereology, Novi Sad, Serbia;

²University Clinical Center of Vojvodina, Clinic of Dermatovenereology Diseases, Novi Sad, Serbia;

³University of Novi Sad, Faculty of Medicine, Department of General Education Subjects, Novi Sad, Serbia;

⁴University Clinical Center of Vojvodina, Center for Laboratory Diagnostics, Novi Sad, Serbia;

⁵University of Novi Sad, Faculty of Pharmacy, Novi Sad, Serbia

SUMMARY

Atopic dermatitis is an inflammatory skin disease that is characterized by a chronic-relapsing course and a pronounced feeling of itching. Altered production of structural proteins, lipids and antimicrobial peptides results in epidermal impairment, leading to the early onset of disease, more severe lesions and numerous comorbidities. Atopic dermatitis has recently been recognized as a systemic type 2 inflammation and emerging novel therapeutic modalities reflect sophisticated molecular and immunopathological pathways. The aim of this article is to provide a thorough review of the existing knowledge regarding the most significant immunological aspects of the development and progression of atopic dermatitis.

Keywords: atopic eczema; epidermis; inflammation; Th2 cells

INTRODUCTION

Atopic dermatitis (AD) is a dermatosis characterized by pruritus and typical cutaneous lesions that vary through acute, subacute, and chronic phases [1–6]. It affects approximately 20% of children and 2–10% of adults [1, 2, 4]. Additionally, 40–60% of patients with atopic dermatitis also have another form of atopy, such as asthma, allergic rhinitis or food allergy [1, 2, 4, 6]. The pathogenesis of AD reflects a multifactorial condition, with genetics underpinning epidermal barrier impairment as an initial state, triggered by environmental insults (allergens, irritants, pollutants) and microbiome alteration, contributing to the sustained type 2 inflammation [1, 5]. This article seeks to provide a thorough review of the current knowledge with regard to key mechanisms involved in the development and progression of atopic dermatitis.

EPIDERMAL BARRIER IN AD

A damaged skin barrier in some hereditary diseases is directly related to the disease phenotype, while in atopic dermatitis it represents an initial condition that triggers further inflammation and sensitization [5, 7–9]. Abnormalities in the production of structural proteins, lipids, and antimicrobial peptides result in skin barrier dysfunction, early onset of disease, more extensive lesions and a greater number of comorbidities [1, 2, 5, 10]. An impaired barrier culminates in increased permeability of the epidermis, heightened transepidermal water

loss (TEWL), compromised natural moisturization of the skin, dysregulated skin surface pH, and penetration of exogenous agents: irritants, aeroallergens, contact sensitizers, and microbial products [5, 11–14]. Epidermal barrier deficiency manifests clinically as extremely dry skin, followed by intense pruritus, scratching and rubbing, creating ‘itch-scratch’ cycle that underlies secondary bacterial infections and contact sensitization [5, 14–17].

The cornerstone of the skin barrier is the integrity of the stratum corneum. The main components of corneocytes are keratin filaments organized by filaggrin (FLG), which form the basis of the extracellular lipid matrix [2]. Defective FLG or its reduction contributes to the reduced production of acidic metabolites and an increase in skin pH, reduced activity of enzymes involved in lipid metabolism (beta-glucocerebrosidase, acid sphingomyelinase), accumulation and impaired secretion of lamellar bodies, and disruption of the entire lipid organization of the stratum corneum [7, 18, 19]. Apart from FLG, other essential constituents are loricrin, involucrin, corneodesmosin, SPRR3/4 (small proline-rich proteins) and claudin-1 and -3, which are vital for epidermal integrity [19]. Additionally, diminished ceramide levels in the stratum corneum contribute to increased TEWL and epidermal damage. Significant accumulation of very short ceramide chains and reduced ceramide/cholesterol ratio are present in AD patients [20].

Environmental agents contribute to impaired barrier permeability, affecting its structure and function, while simultaneously triggering keratinocyte activation and alarmin

Received • Примљено:
November 19, 2025

Revised • Ревизија:
February 19, 2026

Accepted • Прихваћено:
April 19, 2026

Online first: May 28, 2026

Correspondence to:

Sanja JAKOVljević
Bulevar Cara Lazara 76
21000 Novi Sad
sanja.jakovljevic@mf.uns.ac.rs




Figure 1. The ILC2 link between epidermal barrier damage and type 2 inflammation, following environmental insults; figure designed by figurelabs.ai

release – interleukin (IL)-25, IL-33 and thymic stromal lymphopoietin (TSLP), inducing involvement of type 2 innate lymphoid cells (ILC2s) with subsequent type 2 inflammation and IL-4, IL-5 and IL-13 secretion, reflecting the link between the epidermal barrier and inflammation [1, 9, 21, 22]. IL-4 and IL-13 in turn damage the epidermal barrier through altered filaggrin and loricrin expression, with reduced levels of antibacterial peptides, resulting in permanent epidermal dysfunction (Figure 1) [1, 9, 21, 22].

IMMUNE DYSFUNCTION DRIVES DISEASE

Keratinocytes and alarmin release

Thymic stromal lymphopoietin (TSLP), secreted by keratinocytes, plays a paramount role in altered immune response observed in allergic diseases and AD [2, 18]. TSLP, as an interleukin-7 cytokine, acts on dendritic cells to stimulate the naïve CD4⁺ T lymphocytes, inducing the production of IL-4, IL-5 and IL-13 [2, 21]. This induction of Th2 cytokines impacts other immune cells such as mast cells, basophils, innate lymphoid cells (ILCs), macrophages and epithelial cells [2]. Beyond TSLP, keratinocytes also release other alarmins such as IL-25 and IL-33 [2, 18]. IL-33, part of the IL-1 cytokine family, is produced mainly by epithelial cells in response to allergenic and microbial stimuli. It promotes a type 2 immune response by activating ILC2s, leading to the secretion of IL-5 and IL-13 [22]. IL-33 reduces filaggrin expression in keratinocytes, generates the itch sensation, and activates Th1 and Th2 cells. Elevated levels of IL-33 are observed in lesional AD skin, while serum IL-33 levels correlate with disease severity [22].

Langerhans cells and innate lymphoid cells type 2 are highly positioned in the immune hierarchy

Langerhans cells (LC) are pivotal in AD pathogenesis, alongside keratinocytes [23, 24]. LCs participate in the recruitment and polarization of various immune cells in AD [25]. GWAS studies linked CD207 gene mutations to a heightened risk of AD. LCs show increased activity and proliferation in an AD model [25]. LCs are basically antigen-presenting cells and are responsible for the activation of Th2 and B-lymphocytes. It has been experimentally shown that TSLP can induce AD precisely through the activation of LC. Activated LCs secrete CCL17 and CCL22 and thus further polarize the Th2 phenotype [25]. Additionally, LCs facilitate IgE production by mature B-cells and binding through low-affinity receptor FcεRII/CD23 and FcεRI, resulting in IL-16-mediated attraction of Th cells, inflammatory epidermal dendritic cell (IDEC) precursors, and eosinophils. IDECs in turn, bind IgE via FcεRI, polarizing naïve T-cells into Th1 characteristic of chronic AD [25]. LCs also secrete CCL5, enhancing eosinophil infiltration typical of AD [25].

The activation of T-cells, eosinophils, basophils, macrophages, mast cells, and innate lymphoid cells type 2 (ILC2), along with secretion of cytokines, culminates in localized inflammation in the atopic skin [23]. ILC2s are fundamental in shaping the immune response, maintaining tissue homeostasis, and driving inflammation [20]. Elevated levels of active ILC2s present in AD lesions are associated with increased levels of type 2 cytokines and inflammation, whereas decreased numbers of NK cells were noted in the blood of AD patients [20]. ILC2s secrete IL-4, IL-5, IL-9 and IL-13 upon activation by alarmins (TSLP, IL-25, IL-33)




Figure 2. The immunopathogenesis of atopic dermatitis reflects the initial phase of keratinocyte activation, alarmin-stimulated ILC2s and the secretion of IL-4, IL-5 and IL-13, which further promote Th2-driven inflammation in acute atopic dermatitis; Th1 cells with gamma interferon and IL-12 release predominate in the chronic phase; activation of B cells is responsible for IgE secretion; figure designed by figurelabs.ai

or eicosanoids, even in the absence of antigenic stimulation, fostering a Th2 response [22, 26]. Regarding the main immune pathways, the interaction of OX40L/OX40 between stimulated dendritic cells and T cells, may represent a key mechanism in atopic inflammation [1, 9, 21, 22]. The OX40L-OX40 interaction between dendritic cells and T-cells also contributes to this response [22]. OX40 (CD134) expression is enhanced on T cells, following specific T cell receptor activation, OX40L-OX40 mediates the antigen presentation process and plays a significant role in allergic diseases and tumor pathologies. Recent studies indicate that inhibiting OX40-OX40L interactions suppresses T cell-driven inflammation in AD [22, 26].

The persistent “vicious cycle” of immune activation

The inflammatory “vicious cycle” and epidermal barrier damage are initiated by activated keratinocytes and Langerhans cells, which secrete IL-10, IL-12, IL-18, IL-23, IL-17, IL-22, TSLP. This cascade further triggers Th2-mediated inflammation and the secretion of cytokines IL-4, IL-13, IL-31 and IL-22, compromising the epidermal barrier by reducing the expression of filaggrin, loricrin, claudin, and periplakin [20, 22, 27]. Concurrently, type 2 cytokines (IL-4, IL-5, IL-13) reactivate ILC2 and eosinophils [23, 27].

The increased production of IgE in AD stimulates mast cells and basophils [5, 26]. IgE can be non-specific (intrinsic AD-iAD) and allergen-specific (extrinsic AD-eAD). Elevated levels of specific IgE increase the risk of developing atopic march [23]. IgE-mediated stimulation of mast cells triggers degranulation and release of histamine,

IL-6, IL-8, PGD₂, αTNF, IL-23, and IL-31 [27]. Specific IgE binds to and activates dendritic epidermal cells and epidermal Langerhans cells that secrete proinflammatory cytokines TSLP, CCL17, CCL18, CCL22, and IL-33, initiating T-cell sensitization and subsequent inflammation [20].

Numerous studies underscore the importance of Th2-mediated inflammation in allergic diseases [28]. Th2 inflammation is a key phenomenon in the onset of immune dysfunction leading to the acute phase of atopic dermatitis characterized by high levels of IL-4 and IL-13. These cytokines activate B lymphocytes to secrete IgE, adversely affecting filaggrin production in a feedback loop, while the release of IL-5 sustains eosinophilia in AD patients [19]. Type 2 inflammatory response is characteristic of antiparasitic and antitoxic effects, and allergic inflammation [28]. This type of immune response initially involves ILC2 and keratinocytes, along with dendritic cells, macrophages and Langerhans cells, extending to the activation of Th2, Tc, NK, B-cells, eosinophils, mast cells and basophilic granulocytes, leading to the secretion of IL-4, IL-5, IL-9, IL-13, IL-31 and IgE, the primary mediators of inflammation in AD (Figure 2) [28]. Clinical studies have already shown the efficacy of monoclonal antibodies directed against IL-4, IL-13, and IL-31, or their receptors, in the treatment of AD [1, 5, 22].

In chronic AD lesions, the Th1-mediated immune response predominates, featuring gamma-interferon and IL-12 [5, 26]. Over time, some patients also exhibit a Th17/Th22 response that significantly affects keratinocyte lipid metabolism and epidermal function [27, 29]. Dendritic cells and eosinophils produce IL-2 and IL-18 while activating Th1 lymphocytes and promoting secretion of

α TNF, IL-2, IL-12, α IFN, favoring chronic inflammation in AD. Th1-released γ IFN induces keratinocyte apoptosis, whereas IL-17 and IL-22 induce epidermal acanthosis clinically manifested by lichenoid lesions of chronic AD [22, 27]. Chronic AD lesions show elevated levels of IL-5 and IL-12, and decreased levels of IL-4 and IL-13 [27]. Furthermore, increased expression of VEGF originating from keratinocytes and mast cells is detected in AD, mediating angiogenesis in chronic inflammation [27]. Research has demonstrated that IL-17A induces Th2 inflammation, with IL-4 reversibly inhibiting IL-17A. Thus, elevated levels of IL-17A were detected in peripheral blood mononuclear cells in severe AD [30]. $\gamma\delta$ T-cells, a primary source of IL-17A, participate in inflammation, tissue repair, pathogen elimination, immune regulation and tumor suppression [19]. AD patients exhibit elevated levels of circulating V γ 9V δ 2⁺ T-cells, which also produce IL-4 and IL-13, crucial in the pathogenesis of AD. Beyond allergic cutaneous inflammation, $\gamma\delta$ T-cells also contribute to airway allergic inflammation by promoting IgE reactivity and Th2 inflammation [30]. According to previous studies, a subpopulation of lymphocytes, Th9 cells, and IL-9 may also have great potential in the development of allergic inflammation [31]. Elevated IL-9 levels in skin and blood observed in AD patients correlate with the SCORAD index, and findings suggest that IL-9 involved in the pathogenesis of AD originates from activated mast cells, not Th9 cells. However, studies found IL-9 levels correlate with Th9 cells and PU.1 transcript in peripheral blood mononuclear cells, as well as with VEGF expression in AD lesions [31].

Fibroblasts – the secret of AD inflammation

Recent studies highlighted the role of fibroblasts in the pathogenesis of AD. Altered fibroblasts in AD affect keratinocyte terminal differentiation markers, such as filaggrin and loricrin, and lack leukemia inhibitory factor (LIF), impairing epidermal differentiation [32]. In AD, particularly at the epidermal-dermal border, COL6A5+ COL18A1+ fibroblasts show an inflammatory phenotype (CCL2, CCL19, CCL26, IL-32). Abnormal fibroblast adhesion, disturbed synthesis and metabolism of collagen, and damaged epidermal barrier are observed [32]. Conversely, COL18A1 inhibits angiogenesis and disrupts dermal organization by binding to extracellular matrix components in AD. Furthermore, upregulated CCL19 and CCL2, interacting with CCR7, CCR1 and CCR2 on T-lymphocytes and dendritic cells, contribute to the infiltration of type 2 inflammatory response cells [32]. In addition, fibroblasts interact with Th2/Th22 and TRM (tissue-resident memory T cells) cells via CXCL12, promoting allergic inflammation in AD [32]. Experimental evidence has shown fibroblast-eosinophil interaction could play a significant role in the inflammatory cascade. In cell cultures, IL-37b inhibits IL-31/IL-33-induced expression of α TNF, IL-6, CXCL8, CCL2, and CCL5, promoting autophagic mechanisms through regulation of the AMPK-mTOR signaling pathway [32]. Namely, elevated levels of IL-33 and PRG4 inhibit NF- κ B activation, a key regulatory inflammatory mechanism.

Deletion of the *Ikkb* (inhibitor of nuclear factor kappa-B kinase subunit beta) gene leads to the development of AD manifestations, increased expression of CCL11, infiltration of eosinophils and Th2 inflammation [32].

The JAK/STAT signaling pathway as an integral part of AD inflammation

The JAK/STAT signaling pathway represents a central mechanism in modifying multiple immune processes in AD pathogenesis [26, 33, 34]. Previous research indicates that the JAK/STAT pathway enables IL-4, -5, -13, -31, and TSLP to exert effects, epidermal barrier regulation, nerve modulation and pruritus etiopathogenesis [26, 33, 34]. The JAK family includes four kinases associated with receptors: JAK1, JAK2, JAK3 (janus kinase 1/2/3) and TYK2 (tyrosine kinase 2), while STAT (signal transducer and activator of transcription) includes seven proteins: STAT1, STAT2, STAT3, STAT4, STAT5, STAT5a, STAT5b, STAT6 [26, 33, 34]. The proposed mechanism of the JAK/STAT signaling pathway includes phosphorylation of intracellular receptor domain, subsequently recruiting and inducing phosphorylated STAT dimerization that culminates in translocation into the nucleus and regulation of gene transcription by binding to DNA [26, 33, 34]. TSLP binds to the heterodimeric receptor TSLPR, containing the IL-7R α receptor, and interacts with JAK1 and JAK2, with further STAT5 activation [34]. IL-4 binds to the IL-4R type I receptor, resulting in JAK1 and JAK3 phosphorylation, which activate and phosphorylate the IL-4R α chain (common to IL-13R α 1 in type II IL-4 receptor) and STAT6. IL-4 and IL-13 bind to IL-4R type II leading to JAK1 and TYK2 phosphorylation, STAT3 and STAT6 activation, inducing reduced filaggrin expression, epidermal barrier dysfunction, and increased TSLP, IL-25, IL-33 production in keratinocytes [26, 33, 34]. IL-5 binding to the α subunit of its receptor, and IL-3 and granulocyte-macrophage colony-stimulating factor (GM-CSF) binding to the β subunit, activate and phosphorylate JAK1 and JAK2, as well as STAT, STAT3 and STAT5 [26, 33, 34]. IL-31 binds to its receptor complex's α subunit, containing oncostatin-M-receptor- β (OSMR β). The IL-31R α -OSMR β complex activates JAK1 and JAK2, STAT3 and STAT5, and to a lesser extent, STAT1 [26, 33, 34].

During AD's chronic phase, Th1, Th17 and Th22 subpopulations and cytokines sustain local inflammation, the presence of proinflammatory cytokines, and epidermal hyperplasia [26, 33, 34]. The JAK-STAT signaling pathway indirectly influences differentiation and function of Th17 cells through the activation of STAT3, affecting the release of pro-Th17 cytokines: IL-6, IL-21, and IL-23, and the final production of IL-17. On the other hand, IL-22 after binding to its receptor leads to the phosphorylation of JAK1 and TYK2, and STAT3, STAT1 and STAT5 [26, 33, 34]. Elevated Th1 cytokine levels include γ IFN, IL-12, and granulocyte colony-stimulating factor (G-CSF). IL-12 primarily stimulates naïve T-cell differentiation into the Th1 subpopulation. IL-12 receptor beta subunits binding activates JAK2 and TYK2, and STAT4, as well as STAT1, STAT3, and STAT5, to a lesser extent [26, 33, 34]. γ IFN,

playing its pathophysiological role in epidermal dysfunction by reducing ceramide and long-chain fatty acids expression, upon its receptor binding, activates JAK1 and JAK2, and STAT1 [26, 33, 34]. JAK1's implication in epidermal barrier dysfunction is linked to JAK1-dependent exertion of IL-4, IL-5, IL-13, IL-22, TSLP, and γ IFN [26, 33, 34]. Abundant JAK1 activation is associated with cutaneous overexpression of serine proteases and epidermal degradation, whereas STAT3, as a key transcription factor, impacts keratinocyte differentiation and thus skin integrity maintenance. Inhibition of JAK1/JAK2/JAK3/STAT3 axis benefits epidermal barrier functionality by enhancing filaggrin, loricrin and other factors responsible for epidermal homeostasis [26, 33, 34].

NOVEL DISCOVERIES AND EMERGING THERAPEUTIC TARGETS

Recent studies highlight the role of small molecules, receptors, ion channels, transcription factors and signaling pathways in AD development and treatment. Among these, phosphodiesterase-4 (PDE4) plays a crucial role in AD pathogenesis, with four subtypes, of which PDE4B particularly impacts the inflammatory response [26]. PDE4 is present in various cells, including basophils, mast cells, neutrophils, eosinophils, monocytes, macrophages, B and T lymphocytes, endothelial cells, and dermal fibroblasts [26, 35]. PDE4 primarily hydrolyzes cyclic adenosine monophosphate - cAMP, or cyclic guanosine monophosphate - cGMP [26, 36]. cAMP affects the regulation of the inflammatory and immune response, with elevated levels of cAMP suppressing lymphocytes and monocytes [26, 36]. AD patients exhibit increased adenylate cyclase levels, leading to accumulation of cAMP and compensatory PDE4 activation [35]. This stimulation of PDE4 results in inadequate cAMP metabolism, with elevated levels of prostaglandin E₂, IL-6 and IL-10 in monocytes of AD patients, contributing to Th1/Th2 imbalance and Th2 cytokines prevalence [35, 36]. Inhibiting PDE4 prevents intracellular cAMP degradation, activation of PKA (protein kinase A) and Epac 1 / Epac 2 (exchange factor directly activated by cAMP 1/2), which lead to the inhibition of NF- κ B mediation, promoting production of anti-inflammatory cytokines via CREB (cAMP-responsive element binding) protein interaction [26, 36]. PDE4 inhibition influences immune functions by regulating inflammatory cytokines, T cell activation, neutrophil degranulation, antigen presentation, epidermal integrity, and oxidative stress suppression [26].

AHR (aryl hydrocarbon receptor) and NRF2 (nuclear factor erythroid 2-related factor 2) are transcription factors of cytoprotective genes involved in detoxification mechanisms and antioxidant activity of enzymes [37]. AHR, located in the cytosol, forms complexes with several proteins [22, 26]. Upon ligand binding, AHR dissociates from other proteins, translocates to the nucleus, and binds to the DNA molecule, regulating target gene expression. These receptors exhibit pro-inflammatory and anti-inflammatory activity after exposure to various exogenous and

endogenous factors. AHR is found in Treg, Th17, Th22, Tc, $\gamma\delta$ T and ILCs [26]. AHR is involved in keratinocyte differentiation and proliferation mechanisms, inflammatory cytokine production, and T-cell immune regulation [22]. Studies confirmed AHR's critical role in FLG expression in human keratinocytes. Activated AHR binds to the EDC (epidermal differentiation complex) locus, regulates transcription factor OVOL1 and stimulates FLG, loricrin and involucrin expression [22]. Additionally, AHR regulates NRF2 activation, inducing expression of cytoprotective genes encoding detox and antioxidant enzymes [22, 38]. NRF2 activation interferes with Th2 cytokines via STAT6 dephosphorylation. NRF2 also suppresses proinflammatory cytokines (IL-6 and IL-1 β) production by impairing NF- κ B transcriptional activity [22]. Modulating AHR and NRF2 inducers achieves significant epidermal barrier regeneration and inflammation suppression in experimental AD models [22, 38, 39].

TLRs, as part of innate immunity, exhibit polymorphism in AD and pathological functions, affecting epidermal barrier repair delay, antimicrobial defense impairment, Th2 inflammation stimulation, Th1 response transition in AD chronicity, pruritus and UV radiation effects [40]. TLR activation is vital in microbial defense. Staphylococcal enterotoxin B increases TLR6 expression on monocytes in AD, while TLR2 stimulation on dendritic cells and monocytes leads to dysfunctional maturation and increased IL-17A production in AD [40]. Additionally, TLR2 activation interferes with IFNGR/JAK/STAT1 signaling pathway, reducing Th1 chemokines expression, while *St. aureus* ligands stimulate TLR2-mediated IL-10 secretion, directing Th1/Th17 response towards Th2 inflammation [40]. TLR agonists showed ameliorating effects on AD symptoms, barrier function and inflammation, while several experimental models underlined the need for careful modulation instead, considering diverse TLR functions in AD and inconsistent expression levels in various stages of the disease [40].

Research has focused on discovering new activation mechanisms for mast cells, crucial in allergic and atopic diseases, which could represent potential targets for novel therapies. MRGPRX2 (Mas-related G protein-coupled receptor-X2) has gained importance in AD pathogenesis research in recent years [41]. MRGPRX2 involves non-IgE-mediated mast cell degranulation [41]. Elevated levels of MRGPRX2 agonists, such as neuropeptide SP, human β -defensin, cortistatin 14, and TSLP, are present in AD [39]. MRGPRX2 is expressed by basophils and eosinophils, in addition to mast cells and sensory neurons. MRGPRX2 facilitates effector cell degranulation, leading to inflammation [41]. Antagonizing MRGPRX2 demonstrated significant improvement of AD phenotypic changes, preservation of involucrin expression and periostin downregulation, suggesting that MRGPRX2 may be a novel therapeutic target in AD [41].

In type 2 allergic diseases, including AD, there is an abnormally increased NLRP3 (NLR family pyrin domain containing 3) inflammasome activation [42]. NLRP3, a protein complex, consists of NLRP3 protein, ASC and

caspase-1. It can be activated via the NF- κ B pathway, ion channels, and lysosome damage [42]. House dust mite allergens stimulate keratinocytes to form the NLRP3 inflammasome, secreting IL-1 β and IL-18 and initiating inflammation [42]. NLRP3 inflammasome activation in keratinocytes increases production of ROS particles and NF- κ B signaling pathway activation. Phosphorylation of p38, ERK and JNK in keratinocytes triggers the MAPK (mitogen-activated protein kinase) signaling pathway and in turn activates the inflammasome via MAPK/AP-1/NF- κ B [42]. NLRP3/IPF4/IL-33 axis activation in keratinocytes is also identified in AD, contributing to disease pathogenesis [42]. Suppressing NLRP3 expression effectively reduces inflammation, highlighting NLRP3 inhibitors' therapeutic potential [42].

CONCLUSION

Given the accelerated implementation of new therapeutic options in clinical practice, such as biologics and small

molecule therapies, we believe that an in-depth review of current knowledge in the field of immunopathogenesis of atopic dermatitis provides an essential overview of the basic principles that modern therapies are based on, while broadening horizons for future research. The coming years are expected to bring an expansion of the application of translational research in treatment and diagnostics, contributing to a more precise individual approach and stratification of patients with atopic dermatitis as well.

Ethics: The authors declare that the article was written in accordance with ethical standards of the Serbian Archives of Medicine as well as ethical standards of medical facilities for each author involved.

ACKNOWLEDGMENT

This paper is part of a doctoral thesis.

Conflict of interest: None declared.

REFERENCES

- Lugović-Mihić L, Meštrović-Štefekov J, Potočnjak I, Cindrić T, Ilić I, Lovrić I, et al. Atopic dermatitis: disease features, therapeutic options, and a multidisciplinary approach. *Life (Basel)*. 2023;13(6):1419. [DOI: 10.3390/life13061419] [PMID: 37374201]
- Mrkić Kobal I, Plavec D, Vlašić Lončarić Ž, Jerković I, Turkalj M. Atopic march or atopic multimorbidity: overview of current research. *Medicina (Kaunas)*. 2023;60(1):21. [DOI: 10.3390/medicina60010021] [PMID: 38256282]
- Lobefaro F, Gualdi G, Di Nuzzo S, Amerio P. Atopic dermatitis: clinical aspects and unmet needs. *Biomedicines*. 2022;10(11):2927. [DOI: 10.3390/biomedicines10112927] [PMID: 36428493]
- Raimondo A, Lembo S. Atopic dermatitis: epidemiology and clinical phenotypes. *Dermatol Pract Concept*. 2021;11(4):e2021146. [DOI: 10.5826/dpc.1104a146] [PMID: 35024238]
- Furue M, Chiba T, Tsuji G, Ulzii D, Kido-Nakahara M, Nakahara T, et al. Atopic dermatitis: immune deviation, barrier dysfunction, IgE autoreactivity and new therapies. *Allergol Int*. 2017;66(3):398–403. [DOI: 10.1016/j.alit.2016.12.002] [PMID: 28057434]
- Jakovljević S, Barjaktarović I, Jakovljević D, Levakov O, Vujanović L. miRNA-146-a, miRNA-21, miRNA-143, miRNA-29-b and miRNA-223 as potential biomarkers for atopic dermatitis. *Clin Pract*. 2025;15(11):192. [DOI: 10.3390/clinpract15110192]
- Mariath LM, Santin JT, Schuler-Faccini L, Kiszewski AE. Inherited epidermolysis bullosa: update on the clinical and genetic aspects. *An Bras Dermatol*. 2020;95(5):551–69. [DOI: 10.1016/j.abd.2020.05.001] [PMID: 32732072]
- Vujanović L, Jovanović M, Golušin Z, Kovačić Dukić S, Jakovljević S, Nišavić M. Inherited epidermolysis bullosa: a case report of several family members in three generations. *Serb J Dermatol Venerol*. 2018;10(1):12–7. [DOI: 10.2478/sjdv-2018-0003]
- Schmuth M, Eckmann S, Moosbrugger-Martinez V, Ortner-Tobider D, Blunder S, Trafoier T, et al. Skin barrier in atopic dermatitis. *J Invest Dermatol*. 2024;144(5):989–1000.e1. [DOI: 10.1016/j.jid.2024.03.006] [PMID: 38643989]
- Jakovljević S, Vujanović L, Ogorelica D, Fejsa Levakov A, Sekulić J. Grover's disease in a patient with atopic dermatitis: a case report. *Med Pregl*. 2021;74(1–2):33–7. [DOI: 10.2298/MPNS2102033J]
- Chong AC, Chwa WJ, Ong PY. Aeroallergens in atopic dermatitis and chronic urticaria. *Curr Allergy Asthma Rep*. 2022;22(7):67–75. [DOI: 10.1007/s11882-022-01033-2] [PMID: 35362938]
- Trimeche K, Lahouel I, Belhadjali H, Salah NB, Youssef M, Zili J. Contact allergy in atopic dermatitis: a prospective study on prevalence, incriminated allergens and clinical insights. *Contact Dermatitis*. 2024;90(5):514–9. [DOI: 10.1111/cod.14494] [PMID: 38151921]
- Vujanović L, Jovanović M, Matić M, Jakovljević S, Golušin Z. Contact sensitization in patients with chronic venous insufficiency and the impact of the disease duration on the risk of occurrence of contact sensitization. *Vojnosanit Pregl*. 2021;78(11):1125–32. [DOI: 10.2298/VSP190821023V]
- Oliva M, Sarkar MK, March ME, Saeidian AH, Mentch FD, Hsieh CL, et al. Multi-ancestry genome-wide association meta-analysis identifies novel loci in atopic dermatitis. *medRxiv* [Preprint]. 2024:2024.06.17.24308897. [DOI: 10.1101/2024.06.17.24308897] [PMID: 38946956]
- Nedorost S, Hammond M. Art of prevention: allergic sensitization through damaged skin: atopic, occupational, and stasis dermatitis. *Int J Womens Dermatol*. 2020;6(5):381–3. [DOI: 10.1016/j.ijwd.2020.08.004] [PMID: 33898703]
- Wee C, Tan CH, Zhao X, Yew YW, Goon A. Pattern of contact sensitization in patients with and without atopic dermatitis in an Asian dermatology center. *Contact Dermatitis*. 2022;86(5):398–403. [DOI: 10.1111/cod.14068] [PMID: 35133669]
- Vujanović L, Jakovljević S, Golušin Z, Levakov O. Contact sensitization to allergens of biological origin from the Compositae family and original extracts of ubiquitous weed plants of Vojvodina among patients with chronic venous insufficiency. *Indian J Dermatol*. 2022;67(5):625. [DOI: 10.4103/ijd.ijd_705_21] [PMID: 36865828]
- Otsuka A, Nomura T, Rerknimitr P, Seidel JA, Honda T, Kabashima K. The interplay between genetic and environmental factors in the pathogenesis of atopic dermatitis. *Immunol Rev*. 2017;278(1):246–62. [DOI: 10.1111/imr.12545] [PMID: 28658541]
- Nedoszytko B, Reszka E, Gutowska-Owsiak D, Trzeciak M, Lange M, Jarczak J, et al. Genetic and epigenetic aspects of atopic dermatitis. *Int J Mol Sci*. 2020;21(18):6484. [DOI: 10.3390/ijms21186484] [PMID: 32899887]
- Wrześniewska M, Wołoszczak J, Świrkosz G, Gomułka K. The role of the microbiota in the pathogenesis and treatment of atopic dermatitis: a literature review. *Int J Mol Sci*. 2024;25(12):6539. [DOI: 10.3390/ijms25126539] [PMID: 38928245]
- Tham EH, Leung DY. Mechanisms by which atopic dermatitis predisposes to food allergy and the atopic march. *Allergy Asthma Immunol Res*. 2019;11(1):4–15. [DOI: 10.4168/aa.2019.11.1.4] [PMID: 30479073]
- Tsuji G, Yamamura K, Kawamura K, Kido-Nakahara M, Ito T, Nakahara T. Novel therapeutic targets for the treatment of atopic dermatitis. *Biomedicines*. 2023;11(5):1303. [DOI: 10.3390/biomedicines11051303] [PMID: 37238974]

23. Yang L, Fu J, Zhou Y. Research progress in atopic march. *Front Immunol.* 2020;11:1907. [DOI: 10.3389/fimmu.2020.01907] [PMID: 32973790]
24. Schuler CF 4th, Tsoi LC, Billi AC, Harms PW, Weidinger S, Gudjonsson JE. Genetic and immunological pathogenesis of atopic dermatitis. *J Invest Dermatol.* 2024;144(5):954–68. [DOI: 10.1016/j.jid.2023.10.019] [PMID: 38085213]
25. Pan Y, Hochgerner M, Cichoń MA, Benezeder T, Bieber T, Wolf P. Langerhans cells: central players in the pathophysiology of atopic dermatitis. *J Eur Acad Dermatol Venereol.* 2025;39(2):278–89. [DOI: 10.1111/jdv.20291] [PMID: 39157943]
26. Gatmaitan JG, Lee JH. Challenges and future trends in atopic dermatitis. *Int J Mol Sci.* 2023;24(14):11380. [DOI: 10.3390/ijms241411380] [PMID: 37511138]
27. De Simoni E, Candelora M, Belleghia S, Rizzetto G, Molinelli E, Capodaglio I, et al. Role of antioxidants supplementation in the treatment of atopic dermatitis: a critical narrative review. *Front Nutr.* 2024;11:1393673. [DOI: 10.3389/fnut.2024.1393673] [PMID: 38933878]
28. Ogulur I, Mitamura Y, Yazici D, Pat Y, Ardicli S, Li M, et al. Type 2 immunity in allergic diseases. *Cell Mol Immunol.* 2025;22(3):211–42. [DOI: 10.1038/s41423-025-01261-2] [PMID: 39962262]
29. Cavallo A, Camera E, Maiellaro M, Bottillo G, Mosca S, Kovacs D, et al. Effects of Th1/Th17 and Th2 cytokines on lipid metabolism in differentiated keratinocytes. *Front Physiol.* 2025;16:1387128. [DOI: 10.3389/fphys.2025.1387128] [PMID: 40046180]
30. Chojnacka-Purpurowicz J, Owczarczyk-Saczonek A, Nedoszytko B. The role of gamma delta T lymphocytes in physiological and pathological condition: focus on psoriasis, atopic dermatitis, autoimmune disorders, cancer and lymphomas. *Int J Mol Sci.* 2024;25(14):7960. [DOI: 10.3390/ijms25147960] [PMID: 39063202]
31. Angkasekwinai P. Th9 cells in allergic disease. *Curr Allergy Asthma Rep.* 2019;19(5):29. [DOI: 10.1007/s11882-019-0860-8] [PMID: 30915580]
32. He Y, Han Z, Zhang Q, Liu L, Chang J. Role of fibroblasts in nonfibrotic autoimmune skin diseases. *Mol Med.* 2024;30(1):178. [DOI: 10.1186/s10020-024-00949-x] [PMID: 39420283]
33. Ali S, Ion A, Orzan OA, Bălăceanu-Gurău B. Emerging treatments and new vehicle formulations for atopic dermatitis. *Pharmaceutics.* 2024;16(11):1425. [DOI: 10.3390/pharmaceutics16111425] [PMID: 39598548]
34. Huang IH, Chung WH, Wu PC, Chen CB. JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: an updated review. *Front Immunol.* 2022;13:1068260. [DOI: 10.3389/fimmu.2022.1068260] [PMID: 36569854]
35. Guttman-Yassky E, Hanifin JM, Boguniewicz M, Wollenberg A, Bissonnette R, Purohit V, et al. The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition. *Exp Dermatol.* 2019;28(1):3–10. [DOI: 10.1111/exd.13808] [PMID: 30332502]
36. Carmona-Rocha E, Rusiñol L, Puig L. Exploring the therapeutic landscape: a narrative review on topical and oral phosphodiesterase-4 inhibitors in dermatology. *Pharmaceutics.* 2025;17(1):91. [DOI: 10.3390/pharmaceutics17010091] [PMID: 39861739]
37. Edamitsu T, Taguchi K, Okuyama R, Yamamoto M. AHR and NRF2 in skin homeostasis and atopic dermatitis. *Antioxidants (Basel).* 2022;11(2):227. [DOI: 10.3390/antiox11020227] [PMID: 35204110]
38. Salman S, Paulet V, Hardonnière K, Kerdine-Römer S. The role of NRF2 transcription factor in inflammatory skin diseases. *Biofactors.* 2025;51(2):e70013. [DOI: 10.1002/biof.70013] [PMID: 40207460]
39. Kang YM, Kim HM, Lee J, Baek JS, Lee M, An HJ. Indole-3-carbinol alleviates allergic skin inflammation via periostin/thymic stromal lymphopoietin suppression in atopic dermatitis. *Chin Med.* 2024;19(1):177. [DOI: 10.1186/s13020-024-01042-5] [PMID: 39722037]
40. Vafaeian A, Rajabi F, Rezaei N. Toll-like receptors in atopic dermatitis: pathogenesis and therapeutic implications. *Heliyon.* 2025;11(3):e42226. [DOI: 10.1016/j.heliyon.2025.e42226] [PMID: 40007792]
41. Wong TK, Choi YG, Li PH, Chow BKC, Kumar M. MRGPRX2 antagonist GE1111 attenuated DNFB-induced atopic dermatitis in mice by reducing inflammatory cytokines and restoring skin integrity. *Front Immunol.* 2024;15:1406438. [DOI: 10.3389/fimmu.2024.1406438] [PMID: 38817611]
42. Xu S, Wang D, Tan L, Lu J. The role of NLRP3 inflammasome in type 2 inflammation related diseases. *Autoimmunity.* 2024;57(1):2310269. [DOI: 10.1080/08916934.2024.2310269] [PMID: 38332696]

Атопијски дерматитис – нови увиди у имунопатологију болести

Сања Јаковљевић^{1,2}, Ива Барјактаровић^{3,4}, Дуња Јаковљевић⁵, Оливера Леваков^{1,2}, Љуба Вујановић^{1,2}

¹Универзитет у Новом Саду, Медицински факултет, Катедра за дерматовенеролошке болести, Нови Сад, Србија;

²Универзитетски клинички центар Војводине, Клиника за кожно-венеричне болести, Нови Сад, Србија;

³Универзитет у Новом Саду, Медицински факултет, Катедра општеобразовних предмета, Нови Сад, Србија;

⁴Универзитетски клинички центар Војводине, Центар за лабораторијску дијагностику, Нови Сад, Србија;

⁵Универзитет у Новом Саду, Фармацеутски факултет, Нови Сад, Србија

САЖЕТАК

Атопијски дерматитис је инфламаторна болест коже коју карактеришу хронично-рецидивајући ток и изражен осећај свраба. Нарушена продукција структурних протеина, липида и антимикробних пептида доводи до оштећења епидермиса и последичног раног настанка болести, изражених лезија и бројних коморбидитета. Атопијски дерматитис је недавно препознат као системска инфламација типа 2, што

уз нове терапијске модалитете одражава софистициране молекуларне и имунопатолошке путеве. Циљ овог чланка је да пружи свеобухватан преглед досадашњих сазнања о најзначајнијим имунолошким аспектима развоја и прогресије атопијског дерматитиса.

Кључне речи: атопијски екцем; епидермис; инфламација; Th2 ћелије